Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of inherited metabolic disease 2010-12, Vol.33 (6), p.759-767
Hauptverfasser: Valstar, Marlies J, Bruggenwirth, Hennie T, Olmer, Renske, Wevers, Ron A, Verheijen, Frans W, Poorthuis, Ben J, Halley, Dicky J, Wijburg, Frits A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 767
container_issue 6
container_start_page 759
container_title Journal of inherited metabolic disease
container_volume 33
creator Valstar, Marlies J
Bruggenwirth, Hennie T
Olmer, Renske
Wevers, Ron A
Verheijen, Frans W
Poorthuis, Ben J
Halley, Dicky J
Wijburg, Frits A
description Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.
doi_str_mv 10.1007/s10545-010-9199-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2992652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2198550491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5709-ed7b4c1666f29fd734dafb128ff12015b9e5885d83a7fc2a04abbeae33f3fedd3</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhSMEokPhB7CBCKliFfAjTuINEpRXUCsW0LV148eMq4yd2kmr_HscMrTAAlaW5e8cn3tPlj3F6BVGqH4dMWIlKxBGBcecF_O9bINZTQtSVex-tkG4xEXDGTvKHsV4iRDiDWMPsyOCGkY4ZZtMnE_SD76fI0i5g2CVjzbm4zzovG3bd_ke5nwIWvm9deDG_uctajfmN3bc5eByGEftJhi1ymVvnZXQ58NOO7-YPM4eGOijfnI4j7OLjx--n34uzr5-ak_fnhWS1YgXWtVdKXFVVYZwo2paKjAdJo0xmCDMOq5Z0zDVUKiNJIBK6DoNmlJDjVaKHmdvVt9h6vZayRQwQC-GYPcQZuHBij9fnN2Jrb8WhHNSMZIMXh4Mgr-adBzF3kap-x6c9lMUDWasrEqKE_niL_LST8Gl6RJUUtYgutjhFZLBxxi0uY2CkVjKE2t5IpUnlvLEnDTPfp_hVvGrrQScHACIacsmgJM23nG0wglbuHrlbmyv5___LL605-9RzXhSklUZk8htdbib7V-5n68iA17ANqRIF99SaxRhjmuGKP0B5RvPbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>814358032</pqid></control><display><type>article</type><title>Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Access via Wiley Online Library</source><creator>Valstar, Marlies J ; Bruggenwirth, Hennie T ; Olmer, Renske ; Wevers, Ron A ; Verheijen, Frans W ; Poorthuis, Ben J ; Halley, Dicky J ; Wijburg, Frits A</creator><creatorcontrib>Valstar, Marlies J ; Bruggenwirth, Hennie T ; Olmer, Renske ; Wevers, Ron A ; Verheijen, Frans W ; Poorthuis, Ben J ; Halley, Dicky J ; Wijburg, Frits A</creatorcontrib><description>Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.</description><identifier>ISSN: 0141-8955</identifier><identifier>EISSN: 1573-2665</identifier><identifier>DOI: 10.1007/s10545-010-9199-y</identifier><identifier>PMID: 20852935</identifier><identifier>CODEN: JIMDDP</identifier><language>eng</language><publisher>Dordrecht: Dordrecht : Springer Netherlands</publisher><subject>Algorithms ; Biochemistry ; Biological and medical sciences ; Carbohydrates (enzymatic deficiencies). Glycogenosis ; Cause of Death ; Cells, Cultured ; Child ; Child, Preschool ; Delivery, Obstetric - methods ; Delivery, Obstetric - statistics &amp; numerical data ; Diagnosis, Differential ; Errors of metabolism ; Female ; Human Genetics ; Humans ; Infant ; Internal Medicine ; Male ; Medical genetics ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Mucopolysaccharidosis III - classification ; Mucopolysaccharidosis III - diagnosis ; Mucopolysaccharidosis III - epidemiology ; Mucopolysaccharidosis III - mortality ; Original ; Original Article ; Pediatrics ; Phenotype ; Pregnancy ; Registries</subject><ispartof>Journal of inherited metabolic disease, 2010-12, Vol.33 (6), p.759-767</ispartof><rights>The Author(s) 2010</rights><rights>2010 The Author(s)</rights><rights>2015 INIST-CNRS</rights><rights>SSIEM and Springer 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5709-ed7b4c1666f29fd734dafb128ff12015b9e5885d83a7fc2a04abbeae33f3fedd3</citedby><cites>FETCH-LOGICAL-c5709-ed7b4c1666f29fd734dafb128ff12015b9e5885d83a7fc2a04abbeae33f3fedd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10545-010-9199-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10545-010-9199-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27928,27929,41492,42561,45578,45579,51323</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23619355$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20852935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valstar, Marlies J</creatorcontrib><creatorcontrib>Bruggenwirth, Hennie T</creatorcontrib><creatorcontrib>Olmer, Renske</creatorcontrib><creatorcontrib>Wevers, Ron A</creatorcontrib><creatorcontrib>Verheijen, Frans W</creatorcontrib><creatorcontrib>Poorthuis, Ben J</creatorcontrib><creatorcontrib>Halley, Dicky J</creatorcontrib><creatorcontrib>Wijburg, Frits A</creatorcontrib><title>Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype</title><title>Journal of inherited metabolic disease</title><addtitle>J Inherit Metab Dis</addtitle><addtitle>J Inherit Metab Dis</addtitle><description>Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.</description><subject>Algorithms</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Carbohydrates (enzymatic deficiencies). Glycogenosis</subject><subject>Cause of Death</subject><subject>Cells, Cultured</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Delivery, Obstetric - methods</subject><subject>Delivery, Obstetric - statistics &amp; numerical data</subject><subject>Diagnosis, Differential</subject><subject>Errors of metabolism</subject><subject>Female</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Mucopolysaccharidosis III - classification</subject><subject>Mucopolysaccharidosis III - diagnosis</subject><subject>Mucopolysaccharidosis III - epidemiology</subject><subject>Mucopolysaccharidosis III - mortality</subject><subject>Original</subject><subject>Original Article</subject><subject>Pediatrics</subject><subject>Phenotype</subject><subject>Pregnancy</subject><subject>Registries</subject><issn>0141-8955</issn><issn>1573-2665</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkUtv1DAUhSMEokPhB7CBCKliFfAjTuINEpRXUCsW0LV148eMq4yd2kmr_HscMrTAAlaW5e8cn3tPlj3F6BVGqH4dMWIlKxBGBcecF_O9bINZTQtSVex-tkG4xEXDGTvKHsV4iRDiDWMPsyOCGkY4ZZtMnE_SD76fI0i5g2CVjzbm4zzovG3bd_ke5nwIWvm9deDG_uctajfmN3bc5eByGEftJhi1ymVvnZXQ58NOO7-YPM4eGOijfnI4j7OLjx--n34uzr5-ak_fnhWS1YgXWtVdKXFVVYZwo2paKjAdJo0xmCDMOq5Z0zDVUKiNJIBK6DoNmlJDjVaKHmdvVt9h6vZayRQwQC-GYPcQZuHBij9fnN2Jrb8WhHNSMZIMXh4Mgr-adBzF3kap-x6c9lMUDWasrEqKE_niL_LST8Gl6RJUUtYgutjhFZLBxxi0uY2CkVjKE2t5IpUnlvLEnDTPfp_hVvGrrQScHACIacsmgJM23nG0wglbuHrlbmyv5___LL605-9RzXhSklUZk8htdbib7V-5n68iA17ANqRIF99SaxRhjmuGKP0B5RvPbg</recordid><startdate>201012</startdate><enddate>201012</enddate><creator>Valstar, Marlies J</creator><creator>Bruggenwirth, Hennie T</creator><creator>Olmer, Renske</creator><creator>Wevers, Ron A</creator><creator>Verheijen, Frans W</creator><creator>Poorthuis, Ben J</creator><creator>Halley, Dicky J</creator><creator>Wijburg, Frits A</creator><general>Dordrecht : Springer Netherlands</general><general>Springer Netherlands</general><general>Springer</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>C6C</scope><scope>24P</scope><scope>WIN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201012</creationdate><title>Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype</title><author>Valstar, Marlies J ; Bruggenwirth, Hennie T ; Olmer, Renske ; Wevers, Ron A ; Verheijen, Frans W ; Poorthuis, Ben J ; Halley, Dicky J ; Wijburg, Frits A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5709-ed7b4c1666f29fd734dafb128ff12015b9e5885d83a7fc2a04abbeae33f3fedd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Algorithms</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Carbohydrates (enzymatic deficiencies). Glycogenosis</topic><topic>Cause of Death</topic><topic>Cells, Cultured</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Delivery, Obstetric - methods</topic><topic>Delivery, Obstetric - statistics &amp; numerical data</topic><topic>Diagnosis, Differential</topic><topic>Errors of metabolism</topic><topic>Female</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Mucopolysaccharidosis III - classification</topic><topic>Mucopolysaccharidosis III - diagnosis</topic><topic>Mucopolysaccharidosis III - epidemiology</topic><topic>Mucopolysaccharidosis III - mortality</topic><topic>Original</topic><topic>Original Article</topic><topic>Pediatrics</topic><topic>Phenotype</topic><topic>Pregnancy</topic><topic>Registries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valstar, Marlies J</creatorcontrib><creatorcontrib>Bruggenwirth, Hennie T</creatorcontrib><creatorcontrib>Olmer, Renske</creatorcontrib><creatorcontrib>Wevers, Ron A</creatorcontrib><creatorcontrib>Verheijen, Frans W</creatorcontrib><creatorcontrib>Poorthuis, Ben J</creatorcontrib><creatorcontrib>Halley, Dicky J</creatorcontrib><creatorcontrib>Wijburg, Frits A</creatorcontrib><collection>AGRIS</collection><collection>Springer Nature OA/Free Journals</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of inherited metabolic disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valstar, Marlies J</au><au>Bruggenwirth, Hennie T</au><au>Olmer, Renske</au><au>Wevers, Ron A</au><au>Verheijen, Frans W</au><au>Poorthuis, Ben J</au><au>Halley, Dicky J</au><au>Wijburg, Frits A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype</atitle><jtitle>Journal of inherited metabolic disease</jtitle><stitle>J Inherit Metab Dis</stitle><addtitle>J Inherit Metab Dis</addtitle><date>2010-12</date><risdate>2010</risdate><volume>33</volume><issue>6</issue><spage>759</spage><epage>767</epage><pages>759-767</pages><issn>0141-8955</issn><eissn>1573-2665</eissn><coden>JIMDDP</coden><abstract>Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.</abstract><cop>Dordrecht</cop><pub>Dordrecht : Springer Netherlands</pub><pmid>20852935</pmid><doi>10.1007/s10545-010-9199-y</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0141-8955
ispartof Journal of inherited metabolic disease, 2010-12, Vol.33 (6), p.759-767
issn 0141-8955
1573-2665
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2992652
source MEDLINE; SpringerNature Journals; Access via Wiley Online Library
subjects Algorithms
Biochemistry
Biological and medical sciences
Carbohydrates (enzymatic deficiencies). Glycogenosis
Cause of Death
Cells, Cultured
Child
Child, Preschool
Delivery, Obstetric - methods
Delivery, Obstetric - statistics & numerical data
Diagnosis, Differential
Errors of metabolism
Female
Human Genetics
Humans
Infant
Internal Medicine
Male
Medical genetics
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Mucopolysaccharidosis III - classification
Mucopolysaccharidosis III - diagnosis
Mucopolysaccharidosis III - epidemiology
Mucopolysaccharidosis III - mortality
Original
Original Article
Pediatrics
Phenotype
Pregnancy
Registries
title Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A04%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mucopolysaccharidosis%20type%20IIIB%20may%20predominantly%20present%20with%20an%20attenuated%20clinical%20phenotype&rft.jtitle=Journal%20of%20inherited%20metabolic%20disease&rft.au=Valstar,%20Marlies%20J&rft.date=2010-12&rft.volume=33&rft.issue=6&rft.spage=759&rft.epage=767&rft.pages=759-767&rft.issn=0141-8955&rft.eissn=1573-2665&rft.coden=JIMDDP&rft_id=info:doi/10.1007/s10545-010-9199-y&rft_dat=%3Cproquest_pubme%3E2198550491%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=814358032&rft_id=info:pmid/20852935&rfr_iscdi=true